Long-term epidemiological survey of hepatitis B virus infection in a hyperendemic area (Afragola, southern Italy): results of a pilot vaccination project

被引:21
作者
Da Villa, G
Piccinino, F
Scolastico, C
Fusco, M
Piccinino, R
Sepe, A
机构
[1] WHO, Collaborating Ctr, Italian Inst Prevent Liver Dis, I-80132 Naples, Italy
[2] Univ Naples 2, Sch Med, Inst Infect Dis, Naples, Italy
来源
RESEARCH IN VIROLOGY | 1998年 / 149卷 / 05期
关键词
HBV; vaccination; epidemiology; survey; Italy;
D O I
10.1016/S0923-2516(99)89004-9
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In 1983, a pilot project of universal hepatitis B vaccination was introduced in a hyperendemic area in southern Italy (Afragola) and is ongoing to date. In this area before the start of vaccination, we found significant evidence of HBV endemicity: the acute viral hepatitis B incidence in the general population averaged 63/100,000; the HBsAg and anti-HBc prevalence rates were 13.4% and 66.9%, respectively; there was involvement of hepatitis B virus (HBV) in 48.1% of chronic liver pathologies (46.3% in chronic viral hepatitis, 49.5% in cirrhosis and 71.7% in hepatocellular carcinoma cases). We studied the acute viral hepatitis incidence during the vaccination period from 1983 to 1997 and compared the HBsAg and anti-HBc prevalences in 1978 to those in 1997, after 15 years of vaccination. The HBV-related chronic pathology prevalence was also studied. We found a remarkable drop in the acute viral hepatitis incidence, from an average annually of 63/100,000 in the five years before vaccination to 3/100,000 in the last five years of vaccination. In addition, the HBsAg carrier prevalence in the general population decreased from 13.4% in 1978 to 3.7% in 1997. The percentage dropped in children and adolescents from 6.8% to 0.7%, in young people from 10.2% to 1.1% and in adults from 15.8% to 4.0%. The anti-HBc carrier prevalence, found to be 66.9% in 1978, was 34.2% in 1997. Finally, we found a much less significant involvement of HBV in chronic liver pathologies; in fact, it was present in only 18.2% of cases in 1997 and in 48.2% in 1982. In the light of the data, we can assert that universal hepatitis B vaccination has had a substantial effect on HBV endemicity in the Afragola area. We believe that the reduction found in the incidence of acute viral hepatitis B and HBV-related chronic liver pathologies is connected to the decrease in HBV carriers in the area, which therefore reduces the risk of contagion for the unvaccinated.
引用
收藏
页码:263 / 270
页数:8
相关论文
共 12 条
[1]  
BLUMBERG BS, 1997, RES VIRO, V148, P92
[2]   Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children [J].
Chang, MH ;
Chen, CJ ;
Lai, MS ;
Hsu, HM ;
Wu, TC ;
Kong, MS ;
Liang, DC ;
Shau, WY ;
Chen, DS .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (26) :1855-1859
[3]  
CHEN DS, 1996, P 9 TRIENN INT S VIR, P635
[4]  
DARDANONI L, 1988, ANN I SUPER SANITA, V24, P235
[5]   HEPATITIS-B VACCINATION - UNIVERSAL VACCINATION OF NEWBORN BABIES AND CHILDREN AT 12 YEARS OF AGE VERSUS HIGH-RISK GROUPS - A COMPARISON IN THE FIELD [J].
DAVILLA, G ;
PICCIOTTOC, L ;
ELIA, S ;
PELUSO, F ;
MONTANARO, F ;
MAISTO, T .
VACCINE, 1995, 13 (13) :1240-1243
[6]   Persistence of anti-HBs in children vaccinated against viral hepatitis B in the first year of life: Follow-up at 5 and 10 years [J].
DaVilla, G ;
Peluso, F ;
Picciotto, L ;
Bencivenga, M ;
Elisa, S ;
Pelliccia, MG .
VACCINE, 1996, 14 (16) :1503-1505
[7]  
DAVILLA G, 1992, J MED VIROL, V36, P276
[8]  
LEE MK, 1995, THESIS SEOUL NATL U
[9]  
MASTIO MP, 1996, P 9 TRIENN INT S VIR
[10]  
MCMAHON BJ, 1996, P 9 TRIENN INT S VIR, P702